Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatments & Surgery
Share your love
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, where ophthalmology leaders described a retrospective review of 747 eye-related transfers from 25 hospitals in the New York area. The…
Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026
Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), at EURETINA 2026 in Vienna. A mean best-corrected visual acuity (BCVA) gain of about…
Sight Sciences Introduces OMNI Ultra Surgical System at AAO 2026
Sight Sciences announced on October 1, 2026 that it would debut its OMNI Ultra Surgical System, the latest version of its implant-free minimally invasive glaucoma surgery (MIGS) platform, at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New…
SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma
SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced Vision Science (AVS), its existing intraocular lens (IOL) manufacturer, for about $13 million. The deal gives SpyGlass direct control over a key component of its investigational BIM-IOL system,…
International Glaucoma Symposium highlights the meeting point of practice and technology | Ophthalmology Times
The 2nd International Glaucoma Symposium underscores how AI and advanced imaging are becoming integral to modern glaucoma diagnosis and management. (Image credit: AdobeStock/OngCaLucK) The International Glaucoma Symposium was created to close the gap between cutting-edge research and real-world clinical decision-making…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation | Ophthalmology Times
(Image Credit: ADobeStock/New Africa) A large international study1 that evaluated the properties of dry eye drops showed that the commercially available formulations exhibited varying degrees of shear-thinning behavior, which affects the impact on the ocular surface. Ulrich Graf, PhD, the…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…
FDA clears Novaliq’s Investigational New Drug application for NOV05 | Ophthalmology Times
(Image Credit: AdobeStock/Stock Contributor) The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU). NOV05,…